| Literature DB >> 31929588 |
Josh Naunton1, Christopher Harrison2, Helena Britt3, Terrence Haines4, Peter Malliaras1.
Abstract
OBJECTIVE: To describe general practitioner's (GP's) current management of rotator cuff related shoulder pain (RCRP) in Australia and identify if this is consistent with recommended care and best available evidence. The secondary aim was to determine if GP management of RCRP changed over time.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31929588 PMCID: PMC6957186 DOI: 10.1371/journal.pone.0227688
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Rate of shoulder pain problems management per 1,000 GP-patient encounters (n = 488,100), April 2011-March 2016, by problem status.
| New cases | Seen previously Rate per 1,000 encounters | Status not recorded | Total | |
|---|---|---|---|---|
| 2.26 | 2.20 | 0.65 | ||
| 1.35 | 1.28 | 0.41 | ||
| 0.19 | 0.57 | 0.13 | ||
| 0.04 | 0.06 | 0.02 | ||
| 1.88 | 1.92 | 0.90 | ||
Univariate and multivariate patient and GP characteristic specific management rate of RCRP problems per 1,000 encounters April 2011-March 2016.
| Sample size (n) | Characteristic specific Rotator cuff related pain problems managed per 1,000 encounters | Odds ratios (multiple logistic regression) | |
|---|---|---|---|
| PATIENT CHARACTERISTICS | |||
| Not significant | |||
| Male | 195,991 | 5.5 (5.2–5.9) | - |
| Female | 287,848 | 4.8 (4.5–5.1) | - |
| P<0.0001 | |||
| 0–14 years | 55,289 | 0.1 (0.0–0.2) | 0.048 (0.022–0.104) |
| 15–24 years | 39,075 | 1.5 (1.1–1.9) | 0.515 (0.355–0.748) |
| 25–44 years | 107,575 | 4.0 (3.6–4.4) | 1.355 (1.033–1.778) |
| 45–64 years | 132,027 | 8.6 (8.0–9.1) | 2.865 (2.227–3.686) |
| 65–84 years | 123,224 | 6.3 (5.8–6.8) | 2.246 (1.749–2.884) |
| 85+ years | 26,764 | 2.7 (2.1–3.4) | Reference group |
| P = 0.0051 | |||
| Most advantaged | 288,605 | 4.8 (4.5–5.1) | 0.871 (0.791–0.959) |
| Most disadvantaged | 189,031 | 5.7 (5.3–6.1) | Reference group |
| P = 0.0009 | |||
| Yes | 200,495 | 5.2 (4.8–5.5) | Reference group |
| No | 246,429 | 5.1 (4.8–5.4) | 1.185 (1.072–1.309 |
| Not significant | |||
| Non-English speaking | 38,901 | 5.7 (4.9–6.6) | - |
| English speaking | 430,863 | 5.1 (4.8–5.3) | - |
| Not significant | |||
| Indigenous | 8,820 | 3.6 (2.4–4.9) | - |
| Non-Indigenous | 430,863 | 5.2 (4.9–5.4) | - |
| Not significant | |||
| Major city | 343,500 | 4.9 (4.6–5.2) | - |
| Inner regional | 95,800 | 5.6 (5.1–6.2) | - |
| Outer regional/remote | 47,500 | 5.5 (4.6–6.4) | - |
| P<0.0001 | |||
| Male | 287,700 | 5.7 (5.3–6.0) | Reference group |
| Female | 209,400 | 4.4 (4.0–4.7) | 0.801 (0.722–0.888) |
| Not significant | |||
| <45 years | 128,300 | 4.3 (3.9–4.7) | - |
| 45–54 years | 143,000 | 5.5 (5.1–6.0) | - |
| 55+ years | 213,900 | 5.3 (4.9–5.7) | - |
| Not significant | |||
| Australian graduate | 323,100 | 5.2 (4.9–5.5) | - |
| Overseas graduate | 163,300 | 4.9 (4.5–5.3) | - |
Proportion of occasions at which RCRP was managed with at least one of each of the following actions at encounters.
| New RCRP pain | Old RCRP pain | All RCRP pain | |
|---|---|---|---|
| NSAID | 23.5 (20.9–26.0) | 15.8 (13.6–18.0) | 19.1 (17.6–20.7) |
| Steroid–injection | 15.8 (13.6–18.0) | 22.7 (20.0–25.3) | 19.5 (17.8–21.2) |
| Opioid | 6.5 (5.1–8.0) | 9.9 (8.0–11.7) | 8.0 (6.9–9.1) |
| Panadol | 8.3 (6.7–10.0) | 7.0 (5.4–8.6) | 7.5 (6.4–8.6) |
| Steroid–oral | 0.4 (0.0–0.7) | 0.5 (0.1–0.9) | 0.4 (0.2–0.7) |
| Exercise | 1.0 (0.4–1.6) | 0.7 (0.2–1.1) | 0.8 (0.5–1.2) |
| Medication | 0.2 (0.0–0.4) | 1.0 (0.4–1.6) | 0.6 (0.2–0.9) |
| Physical medicine /rehabilitation | 8.0 (6.3–9.6) | 5.4 (3.9–6.9) | 6.7 (5.6–7.8) |
| Physiotherapist | 12.6 (10.5–14.7) | 11.4 (9.5–13.4) | 12.0 (10.7–13.4) |
| Surgeon | 3.1 (2.0–4.1) | 6.0 (4.6–7.5) | 4.6 (3.8–5.4) |
| Rheumatologist | 0.2 (0.0–0.4) | 0.7 (0.2–1.3) | 0.4 (0.1–0.7) |
| Ultra sound shoulder | 53.0 (50.0–56.1) | 28.8 (26.0–31.6) | 41.2 (39.2–43.3) |
| X-ray shoulder | 19.0 (16.6–21.4) | 3.7 (2.6–4.8) | 11.6 (10.3–12.9) |
| MRI shoulder | 0.5 (0.1–0.8) | 0.6 (0.1–1.0) | 0.5 (0.2–0.8) |
| CT scan shoulder | 0.2 (0.0–0.4) | 0.1 (0.0–0.3) | 0.1 (0.0–0.3) |
Notes: Missing data removed. For some problems, the GP did not indicate whether the problem was new or old.
NSAID: Non-steroidal anti-inflammatory drugs
GP management of RC related shoulder pain by time period (2000–2016).
| 2000–2004 | 2004–2008 | 2008–2012 | 2012–2016 | |
|---|---|---|---|---|
| Management rate | 2.98 | 3.50 | 4.28 | 5.30 |
| Medication | 57.1 (54.0–60.1) | 47.9 (44.9–50.8) | 51.0 (48.5–53.6) | 54.3 (52.0–56.6) |
| NSAID | 33.6 (30.7–36.5) | 22.9 (20.4–25.3) | 20.5 (18.4–22.5) | 18.4 (16.7–20.1) |
| Steroid–Injection | 9.8 (7.9–11.8) | 10.3 (8.3–12.3) | 15.8 (13.9–17.8) | 19.7 (17.8–21.6) |
| Opioid | 6.6 (5.2–8.1) | 6.9 (5.5–8.3) | 7.5 (6.2–8.8) | 8.1 (6.9–9.3) |
| Panadol | 7.1 (5.6–8.6) | 6.7 (5.3–8.1) | 7.0 (5.8–8.2) | 7.4 (6.1–8.6) |
| Steroid–oral | 0.2 (-0.1–0.4) | 0.4 (-0.0–0.8) | 0.1 (-0.0–0.3) | 0.5 (0.2–0.8) |
| Exercise | 2.5 (1.6–3.4) | 1.9 (1.1–2.7) | 2.3 (1.6–3.0) | 0.6 (0.2–0.9) |
| Medication | 0.8 (0.3–1.2) | 0.4 (0.1–0.8) | 0.4 (0.1–0.6) | 0.6 (0.3–0.1) |
| Physical medicine/ rehabilitation | 12.0 (10.0–14.0) | 8.7 (6.9–10.5) | 7.5 (6.2–8.9) | 6.6 (5.4–7.8) |
| Physiotherapist | 10.6 (8.8–12.4) | 11.5 (9.7–13.3) | 11.2 (9.6–12.9) | 12.2 (10.7–13.8) |
| Surgeon | 6.1 (4.7–7.6) | 4.4 (3.3–5.5) | 5.2 (4.1–6.2) | 4.5 (3.6–5.4) |
| Rheumatologist | 1.3 (0.7–2.0) | 0.6 (-0.1–1.2) | 0.5 (0.1–0.8) | 0.3 (0.1–0.6) |
| Ultrasound shoulder | 19.1 (16.8–21.4) | 24.2 (21.7–26.7) | 33.1 (30.7–35.5) | 41.9 (39.6–44.2) |
| X-ray shoulder | 13.7 (11.6–15.8) | 12.1 (10.3–13.9) | 12.2 (10.6–13.9) | 11.8 (10.3–13.2) |
| MRI shoulder | 0.0 | 0.0 | 0.1 (-0.0–0.3) | 0.5 (0.2–0.8) |
| CT scan shoulder | 0.0 | 0.0 | 0.3 (0.0–0.6) | 0.1 (0.0–0.2) |